FBXL12

Across TCGA pan-cancer cohorts, FBXL12 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of FBXL12’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where FBXL12 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types FBXL12 is over-expressed in tumor, although a few such as LSCC and LUAD show the opposite, repressed pattern.

HNSC, LSCC, and LUAD are the cancer types where FBXL12 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FBXL12 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	+0.402	.001	8	view →
LSCC	All	All	−0.230	<.001	6	view →
LUAD	Female	All	−0.459	<.001	5	view →
PDAC	Male	All	−0.308	.014	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

FBXL12–HNSC

Open the HNSC breakdown →